GlassScriptPhysician profile
Neelu Agarwal
NPI 1669561932
$3,387.25
in general payments reported to CMS, 2019-2025
27 companies · $888 in 2025
The $888 reported for 2025 was more than what 83% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $356 · 2020: $468 · 2021: $425 · 2022: $206 · 2023: $298 · 2024: $746 · 2025: $888.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,757 · Consulting Fee: $175.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,757.40 |
| Consulting Fee | $175.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $666.42 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Amgen INC. | $499.35 | 2019-2025 | Prolia, Repatha, Evenity |
| Astrazeneca Pharmaceuticals LP | $481.34 | 2019-2025 | Breztri, Farxiga, Airsupra |
| Lilly USA, LLC | $424.55 | 2019-2025 | Zepbound, Mounjaro, Jardiance |
| Abbvie INC. | $250.88 | 2019-2025 | Ubrelvy |
| Cequr Corporation | $136.27 | 2025 | Cequr Simplicity |
| Amarin Pharma, INC. | $133.29 | 2019-2021 | |
| Radius Health, INC. | $122.17 | 2023-2024 | Tymlos |
| Boehringer Ingelheim Pharmaceuticals, INC. | $74.56 | 2021-2025 | Jardiance |
| Abbott Laboratories | $61.84 | 2021-2024 | Proclaim |
| Phadia US INC. | $59.56 | 2019 | |
| Amneal Pharmaceuticals LLC | $51.10 | 2021-2023 | Unithroid |
| Merz North America, INC. | $43.70 | 2024 | |
| Mannkind Corporation | $43.05 | 2019-2021 | |
| Pfizer INC. | $42.47 | 2024-2025 |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Exact Sciences Corporation | $39.24 | 2024 | Cologuard Collection Kit |
| Genentech USA, INC. | $37.44 | 2019-2020 | |
| Sanofi-Aventis U.S. LLC | $36.34 | 2019-2020 | |
| Galderma Laboratories, L.P. | $34.25 | 2021 | |
| Merck Sharp & Dohme LLC | $25.86 | 2020-2021 | |
| Boston Scientific Corporation | $23.68 | 2023 | |
| Glaxosmithkline, LLC. | $20.77 | 2023 | Shingrix, Arexvy |
| Allergan, INC. | $18.20 | 2020 | |
| Teva Pharmaceuticals USA, INC. | $16.46 | 2019 | |
| Insulet Corporation | $16.04 | 2025 | Omnipod |
| Takeda Pharmaceuticals U.S.A., INC. | $14.40 | 2019 | |
| Kowa Pharmaceuticals America, INC. | $14.02 | 2025 | Zoryve |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Neelu Agarwal listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.